Posted by Michael Wonder on 01 Sep 2020
FDA approves weekly therapy for adult growth hormone deficiency
1 September 2020 - On 28 August 2020, the U.S. FDA approved Sogroya (somapacitan) for adults with growth hormone deficiency.
Sogroya is the first human growth hormone therapy that adult patients only take once a week by injection under the skin; other FDA approved human growth hormone formulations for adults with growth hormone deficiency must be administered daily.
Sogroya was evaluated in a randomised, double-blind, placebo-controlled trial in 300 patients with growth hormone deficiency who had never received growth hormone treatment or had stopped treatment with other growth hormone formulations at least three months before the study.
